Paradigm Biopharmaceuticals Ltd. ( (AU:PAR) ) has issued an update.
Paradigm Biopharmaceuticals Ltd. announced that it has received ethics approval from Australia’s centralised Human Research Ethics Committee for its pivotal PARA_OA_012 Phase 3 trial, which evaluates the safety and efficacy of iPPS for treating knee osteoarthritis. This approval facilitates a streamlined and efficient trial process across multiple Australian sites, with participant recruitment and dosing expected to begin in the second quarter of 2025. The trial, which aims to enroll 466 participants globally, marks a significant step in Paradigm’s mission to bring transformative therapies to osteoarthritis patients, leveraging Advanced Clinical’s expertise in osteoarthritis research.
More about Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patient health and quality of life through the discovery, development, and delivery of pharmaceutical therapies. The company specializes in developing injectable pentosan polysulfate sodium (iPPS) for treating inflammatory diseases, particularly those with inflammatory pathogenesis.
YTD Price Performance: 38.52%
Average Trading Volume: 8,346
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $152.2M
See more data about PAR stock on TipRanks’ Stock Analysis page.